AustralieFrV1, PascalFrancis, Corpus, bibRecord, 001E28

Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis

Identifieur interne : 001E28 ( PascalFrancis/Corpus ); précédent : 001E27; suivant : 001E29

Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis

Auteurs : Michael Walsh ; Fausta Catapano ; Wladimir Szpirt ; Kristian Thorlund ; Annette Bruchfeld ; Loic Guillevin ; Marion Haubitz ; Peter A. Merkel ; CHEN AU PEH ; Charles Pusey ; David Jayne

Source :

American journal of kidney diseases [ 0272-6386 ] ; 2011.

RBID : Pascal:11-0199219

Descripteurs français

Pascal (Inist)
- Echange plasmatique, Rein, Vascularite, Idiopathique, Progressif, Néphropathie glomérulaire, Métaanalyse, Néphrologie, Urologie.

English descriptors

KwdEn :
- Glomerulonephritis, Idiopathic, Kidney, Metaanalysis, Nephrology, Plasma exchange, Progressive, Urology, Vasculitis.

Abstract

Background: Plasma exchange may be effective adjunctive treatment for renal vasculitis. We performed a systematic review and meta-analysis of randomized controlled trials of plasma exchange for renal vasculitis. Study Design: Systematic review and meta-analysis of articles identified from electronic databases, bibliographies, and studies identified by experts. Data were abstracted in parallel by 2 reviewers. Setting & Population: Adults with idiopathic renal vasculitis or rapidly progressive glomerulonephritis. Selection Criteria for Studies: Randomized controlled trials that compared standard care with standard care plus adjuvant plasma exchange in adult patients with either renal vasculitis or idiopathic rapidly progressive glomerulonephritis. Intervention: Adjuvant plasma exchange. Outcome: Composite of end-stage renal disease or death. Results: We identified 9 trials including 387 patients. In a fixed-effects model, the pooled RR for end-stage renal disease or death was 0.80 for patients treated with adjunctive plasma exchange compared with standard care alone (95% CI, 0.65-0.99; P = 0.04). No significant heterogeneity was detected (P = 0.5; I² = 0%). The effect of plasma exchange did not differ significantly across the range of baseline serum creatinine values (P = 0.7) or number of plasma exchange treatments (P = 0.8). The RR for end-stage renal disease was 0.64 (95% CI, 0.47-0.88; P= 0.006), whereas the RR for death alone was 1.01 (95% CI, 0.71-1.4; P= 0.9). Limitations: Although the primary result was statistically significant, there is insufficient statistical information to reliably determine whether plasma exchange decreases the composite of end-stage renal disease or death. Conclusions: Plasma exchange may decrease the composite end point of end-stage renal disease or death in patients with renal vasculitis. Additional trials are required given the limited data available.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0272-6386`
A03		`1`		`@0 Am. j. kidney dis.`
A05				`@2 57`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis`
A11	`01`	`1`		`@1 WALSH (Michael)`
A11	`02`	`1`		`@1 CATAPANO (Fausta)`
A11	`03`	`1`		`@1 SZPIRT (Wladimir)`
A11	`04`	`1`		`@1 THORLUND (Kristian)`
A11	`05`	`1`		`@1 BRUCHFELD (Annette)`
A11	`06`	`1`		`@1 GUILLEVIN (Loic)`
A11	`07`	`1`		`@1 HAUBITZ (Marion)`
A11	`08`	`1`		`@1 MERKEL (Peter A.)`
A11	`09`	`1`		`@1 CHEN AU PEH`
A11	`10`	`1`		`@1 PUSEY (Charles)`
A11	`11`	`1`		`@1 JAYNE (David)`
A14	`01`			`@1 Department of Clinical Epidemiology and Biostatistics, McMaster University @2 Hamilton @3 CAN @Z 1 aut. @Z 4 aut.`
A14	`02`			`@1 Vasculitis and Lupus Clinic, Addenbrooke's Hospital @2 Cambridge @3 GBR @Z 1 aut. @Z 2 aut. @Z 11 aut.`
A14	`03`			`@1 Department of Nephrology, Copenhagen University Hospital, Rigshospitalet @2 Copenhagen @3 DNK @Z 3 aut.`
A14	`04`			`@1 Department of Renal Medicine, Karolinska Institute, Karolinska University Hospital @2 Stockholm @3 SWE @Z 5 aut.`
A14	`05`			`@1 Hopital Cochin, Assistance Publique, Hopitaux de Paris, Universite Paris Descartes @2 Paris @3 FRA @Z 6 aut.`
A14	`06`			`@1 Department ofNephrology and Hypertension, Hannover School of Medicine @2 Hannover @3 DEU @Z 7 aut.`
A14	`07`			`@1 Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine @2 Boston, MA @3 USA @Z 8 aut.`
A14	`08`			`@1 Renal Unit, Royal Adelaide Hospital @2 Adelaide @3 AUS @Z 9 aut.`
A14	`09`			`@1 Renal Section, Division of Medicine, Imperial College London, Hammersmith Hospital @2 London @3 GBR @Z 10 aut.`
A20				`@1 566-574`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 19098 @5 354000192894050130`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 35 ref.`
A47	`01`	`1`		`@0 11-0199219`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 American journal of kidney diseases`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Background: Plasma exchange may be effective adjunctive treatment for renal vasculitis. We performed a systematic review and meta-analysis of randomized controlled trials of plasma exchange for renal vasculitis. Study Design: Systematic review and meta-analysis of articles identified from electronic databases, bibliographies, and studies identified by experts. Data were abstracted in parallel by 2 reviewers. Setting & Population: Adults with idiopathic renal vasculitis or rapidly progressive glomerulonephritis. Selection Criteria for Studies: Randomized controlled trials that compared standard care with standard care plus adjuvant plasma exchange in adult patients with either renal vasculitis or idiopathic rapidly progressive glomerulonephritis. Intervention: Adjuvant plasma exchange. Outcome: Composite of end-stage renal disease or death. Results: We identified 9 trials including 387 patients. In a fixed-effects model, the pooled RR for end-stage renal disease or death was 0.80 for patients treated with adjunctive plasma exchange compared with standard care alone (95% CI, 0.65-0.99; P = 0.04). No significant heterogeneity was detected (P = 0.5; I² = 0%). The effect of plasma exchange did not differ significantly across the range of baseline serum creatinine values (P = 0.7) or number of plasma exchange treatments (P = 0.8). The RR for end-stage renal disease was 0.64 (95% CI, 0.47-0.88; P= 0.006), whereas the RR for death alone was 1.01 (95% CI, 0.71-1.4; P= 0.9). Limitations: Although the primary result was statistically significant, there is insufficient statistical information to reliably determine whether plasma exchange decreases the composite of end-stage renal disease or death. Conclusions: Plasma exchange may decrease the composite end point of end-stage renal disease or death in patients with renal vasculitis. Additional trials are required given the limited data available.
C02	`01`	`X`		`@0 002B14A01`
C02	`02`	`X`		`@0 002B07`
C03	`01`	`X`	`FRE`	`@0 Echange plasmatique @5 02`
C03	`01`	`X`	`ENG`	`@0 Plasma exchange @5 02`
C03	`01`	`X`	`SPA`	`@0 Intercambio plasmático @5 02`
C03	`02`	`X`	`FRE`	`@0 Rein @5 03`
C03	`02`	`X`	`ENG`	`@0 Kidney @5 03`
C03	`02`	`X`	`SPA`	`@0 Riñón @5 03`
C03	`03`	`X`	`FRE`	`@0 Vascularite @5 05`
C03	`03`	`X`	`ENG`	`@0 Vasculitis @5 05`
C03	`03`	`X`	`SPA`	`@0 Vasculitis @5 05`
C03	`04`	`X`	`FRE`	`@0 Idiopathique @5 06`
C03	`04`	`X`	`ENG`	`@0 Idiopathic @5 06`
C03	`04`	`X`	`SPA`	`@0 Idiopático @5 06`
C03	`05`	`X`	`FRE`	`@0 Progressif @5 08`
C03	`05`	`X`	`ENG`	`@0 Progressive @5 08`
C03	`05`	`X`	`SPA`	`@0 Progresivo @5 08`
C03	`06`	`X`	`FRE`	`@0 Néphropathie glomérulaire @5 09`
C03	`06`	`X`	`ENG`	`@0 Glomerulonephritis @5 09`
C03	`06`	`X`	`SPA`	`@0 Nefropatía glomerular @5 09`
C03	`07`	`X`	`FRE`	`@0 Métaanalyse @5 11`
C03	`07`	`X`	`ENG`	`@0 Metaanalysis @5 11`
C03	`07`	`X`	`SPA`	`@0 Meta-análisis @5 11`
C03	`08`	`X`	`FRE`	`@0 Néphrologie @5 12`
C03	`08`	`X`	`ENG`	`@0 Nephrology @5 12`
C03	`08`	`X`	`SPA`	`@0 Nefrología @5 12`
C03	`09`	`X`	`FRE`	`@0 Urologie @5 17`
C03	`09`	`X`	`ENG`	`@0 Urology @5 17`
C03	`09`	`X`	`SPA`	`@0 Urología @5 17`
C07	`01`	`X`	`FRE`	`@0 Appareil urinaire @5 37`
C07	`01`	`X`	`ENG`	`@0 Urinary system @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato urinario @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie de l'appareil circulatoire @5 38`
C07	`02`	`X`	`ENG`	`@0 Cardiovascular disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Pathologie des vaisseaux sanguins @5 39`
C07	`03`	`X`	`ENG`	`@0 Vascular disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Vaso sanguíneo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie de l'appareil urinaire @5 40`
C07	`04`	`X`	`ENG`	`@0 Urinary system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Aparato urinario patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Pathologie du rein @5 41`
C07	`05`	`X`	`ENG`	`@0 Kidney disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Riñón patología @5 41`
N21				`@1 129`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 11-0199219 INIST
ET :	Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis
AU :	WALSH (Michael); CATAPANO (Fausta); SZPIRT (Wladimir); THORLUND (Kristian); BRUCHFELD (Annette); GUILLEVIN (Loic); HAUBITZ (Marion); MERKEL (Peter A.); CHEN AU PEH; PUSEY (Charles); JAYNE (David)
AF :	Department of Clinical Epidemiology and Biostatistics, McMaster University/Hamilton/Canada (1 aut., 4 aut.); Vasculitis and Lupus Clinic, Addenbrooke's Hospital/Cambridge/Royaume-Uni (1 aut., 2 aut., 11 aut.); Department of Nephrology, Copenhagen University Hospital, Rigshospitalet/Copenhagen/Danemark (3 aut.); Department of Renal Medicine, Karolinska Institute, Karolinska University Hospital/Stockholm/Suède (5 aut.); Hopital Cochin, Assistance Publique, Hopitaux de Paris, Universite Paris Descartes/Paris/France (6 aut.); Department ofNephrology and Hypertension, Hannover School of Medicine/Hannover/Allemagne (7 aut.); Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine/Boston, MA/Etats-Unis (8 aut.); Renal Unit, Royal Adelaide Hospital/Adelaide/Australie (9 aut.); Renal Section, Division of Medicine, Imperial College London, Hammersmith Hospital/London/Royaume-Uni (10 aut.)
DT :	Publication en série; Niveau analytique
SO :	American journal of kidney diseases; ISSN 0272-6386; Etats-Unis; Da. 2011; Vol. 57; No. 4; Pp. 566-574; Bibl. 35 ref.
LA :	Anglais
EA :	Background: Plasma exchange may be effective adjunctive treatment for renal vasculitis. We performed a systematic review and meta-analysis of randomized controlled trials of plasma exchange for renal vasculitis. Study Design: Systematic review and meta-analysis of articles identified from electronic databases, bibliographies, and studies identified by experts. Data were abstracted in parallel by 2 reviewers. Setting & Population: Adults with idiopathic renal vasculitis or rapidly progressive glomerulonephritis. Selection Criteria for Studies: Randomized controlled trials that compared standard care with standard care plus adjuvant plasma exchange in adult patients with either renal vasculitis or idiopathic rapidly progressive glomerulonephritis. Intervention: Adjuvant plasma exchange. Outcome: Composite of end-stage renal disease or death. Results: We identified 9 trials including 387 patients. In a fixed-effects model, the pooled RR for end-stage renal disease or death was 0.80 for patients treated with adjunctive plasma exchange compared with standard care alone (95% CI, 0.65-0.99; P = 0.04). No significant heterogeneity was detected (P = 0.5; I² = 0%). The effect of plasma exchange did not differ significantly across the range of baseline serum creatinine values (P = 0.7) or number of plasma exchange treatments (P = 0.8). The RR for end-stage renal disease was 0.64 (95% CI, 0.47-0.88; P= 0.006), whereas the RR for death alone was 1.01 (95% CI, 0.71-1.4; P= 0.9). Limitations: Although the primary result was statistically significant, there is insufficient statistical information to reliably determine whether plasma exchange decreases the composite of end-stage renal disease or death. Conclusions: Plasma exchange may decrease the composite end point of end-stage renal disease or death in patients with renal vasculitis. Additional trials are required given the limited data available.
CC :	002B14A01; 002B07
FD :	Echange plasmatique; Rein; Vascularite; Idiopathique; Progressif; Néphropathie glomérulaire; Métaanalyse; Néphrologie; Urologie
FG :	Appareil urinaire; Pathologie de l'appareil circulatoire; Pathologie des vaisseaux sanguins; Pathologie de l'appareil urinaire; Pathologie du rein
ED :	Plasma exchange; Kidney; Vasculitis; Idiopathic; Progressive; Glomerulonephritis; Metaanalysis; Nephrology; Urology
EG :	Urinary system; Cardiovascular disease; Vascular disease; Urinary system disease; Kidney disease
SD :	Intercambio plasmático; Riñón; Vasculitis; Idiopático; Progresivo; Nefropatía glomerular; Meta-análisis; Nefrología; Urología
LO :	INIST-19098.354000192894050130
ID :	11-0199219

Links to Exploration step

Pascal:11-0199219

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis</title>
<author><name sortKey="Walsh, Michael" sort="Walsh, Michael" uniqKey="Walsh M" first="Michael" last="Walsh">Michael Walsh</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Epidemiology and Biostatistics, McMaster University</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Vasculitis and Lupus Clinic, Addenbrooke's Hospital</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Catapano, Fausta" sort="Catapano, Fausta" uniqKey="Catapano F" first="Fausta" last="Catapano">Fausta Catapano</name>
<affiliation><inist:fA14 i1="02"><s1>Vasculitis and Lupus Clinic, Addenbrooke's Hospital</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Szpirt, Wladimir" sort="Szpirt, Wladimir" uniqKey="Szpirt W" first="Wladimir" last="Szpirt">Wladimir Szpirt</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Nephrology, Copenhagen University Hospital, Rigshospitalet</s1>
<s2>Copenhagen</s2>
<s3>DNK</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thorlund, Kristian" sort="Thorlund, Kristian" uniqKey="Thorlund K" first="Kristian" last="Thorlund">Kristian Thorlund</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Epidemiology and Biostatistics, McMaster University</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bruchfeld, Annette" sort="Bruchfeld, Annette" uniqKey="Bruchfeld A" first="Annette" last="Bruchfeld">Annette Bruchfeld</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Renal Medicine, Karolinska Institute, Karolinska University Hospital</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Guillevin, Loic" sort="Guillevin, Loic" uniqKey="Guillevin L" first="Loic" last="Guillevin">Loic Guillevin</name>
<affiliation><inist:fA14 i1="05"><s1>Hopital Cochin, Assistance Publique, Hopitaux de Paris, Universite Paris Descartes</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Haubitz, Marion" sort="Haubitz, Marion" uniqKey="Haubitz M" first="Marion" last="Haubitz">Marion Haubitz</name>
<affiliation><inist:fA14 i1="06"><s1>Department ofNephrology and Hypertension, Hannover School of Medicine</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Merkel, Peter A" sort="Merkel, Peter A" uniqKey="Merkel P" first="Peter A." last="Merkel">Peter A. Merkel</name>
<affiliation><inist:fA14 i1="07"><s1>Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chen Au Peh" sort="Chen Au Peh" uniqKey="Chen Au Peh" last="Chen Au Peh">CHEN AU PEH</name>
<affiliation><inist:fA14 i1="08"><s1>Renal Unit, Royal Adelaide Hospital</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pusey, Charles" sort="Pusey, Charles" uniqKey="Pusey C" first="Charles" last="Pusey">Charles Pusey</name>
<affiliation><inist:fA14 i1="09"><s1>Renal Section, Division of Medicine, Imperial College London, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jayne, David" sort="Jayne, David" uniqKey="Jayne D" first="David" last="Jayne">David Jayne</name>
<affiliation><inist:fA14 i1="02"><s1>Vasculitis and Lupus Clinic, Addenbrooke's Hospital</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0199219</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0199219 INIST</idno>
<idno type="RBID">Pascal:11-0199219</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001E28</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis</title>
<author><name sortKey="Walsh, Michael" sort="Walsh, Michael" uniqKey="Walsh M" first="Michael" last="Walsh">Michael Walsh</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Epidemiology and Biostatistics, McMaster University</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Vasculitis and Lupus Clinic, Addenbrooke's Hospital</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Catapano, Fausta" sort="Catapano, Fausta" uniqKey="Catapano F" first="Fausta" last="Catapano">Fausta Catapano</name>
<affiliation><inist:fA14 i1="02"><s1>Vasculitis and Lupus Clinic, Addenbrooke's Hospital</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Szpirt, Wladimir" sort="Szpirt, Wladimir" uniqKey="Szpirt W" first="Wladimir" last="Szpirt">Wladimir Szpirt</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Nephrology, Copenhagen University Hospital, Rigshospitalet</s1>
<s2>Copenhagen</s2>
<s3>DNK</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thorlund, Kristian" sort="Thorlund, Kristian" uniqKey="Thorlund K" first="Kristian" last="Thorlund">Kristian Thorlund</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Clinical Epidemiology and Biostatistics, McMaster University</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bruchfeld, Annette" sort="Bruchfeld, Annette" uniqKey="Bruchfeld A" first="Annette" last="Bruchfeld">Annette Bruchfeld</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Renal Medicine, Karolinska Institute, Karolinska University Hospital</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Guillevin, Loic" sort="Guillevin, Loic" uniqKey="Guillevin L" first="Loic" last="Guillevin">Loic Guillevin</name>
<affiliation><inist:fA14 i1="05"><s1>Hopital Cochin, Assistance Publique, Hopitaux de Paris, Universite Paris Descartes</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Haubitz, Marion" sort="Haubitz, Marion" uniqKey="Haubitz M" first="Marion" last="Haubitz">Marion Haubitz</name>
<affiliation><inist:fA14 i1="06"><s1>Department ofNephrology and Hypertension, Hannover School of Medicine</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Merkel, Peter A" sort="Merkel, Peter A" uniqKey="Merkel P" first="Peter A." last="Merkel">Peter A. Merkel</name>
<affiliation><inist:fA14 i1="07"><s1>Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chen Au Peh" sort="Chen Au Peh" uniqKey="Chen Au Peh" last="Chen Au Peh">CHEN AU PEH</name>
<affiliation><inist:fA14 i1="08"><s1>Renal Unit, Royal Adelaide Hospital</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pusey, Charles" sort="Pusey, Charles" uniqKey="Pusey C" first="Charles" last="Pusey">Charles Pusey</name>
<affiliation><inist:fA14 i1="09"><s1>Renal Section, Division of Medicine, Imperial College London, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jayne, David" sort="Jayne, David" uniqKey="Jayne D" first="David" last="Jayne">David Jayne</name>
<affiliation><inist:fA14 i1="02"><s1>Vasculitis and Lupus Clinic, Addenbrooke's Hospital</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">American journal of kidney diseases</title>
<title level="j" type="abbreviated">Am. j. kidney dis.</title>
<idno type="ISSN">0272-6386</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">American journal of kidney diseases</title>
<title level="j" type="abbreviated">Am. j. kidney dis.</title>
<idno type="ISSN">0272-6386</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Glomerulonephritis</term>
<term>Idiopathic</term>
<term>Kidney</term>
<term>Metaanalysis</term>
<term>Nephrology</term>
<term>Plasma exchange</term>
<term>Progressive</term>
<term>Urology</term>
<term>Vasculitis</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Echange plasmatique</term>
<term>Rein</term>
<term>Vascularite</term>
<term>Idiopathique</term>
<term>Progressif</term>
<term>Néphropathie glomérulaire</term>
<term>Métaanalyse</term>
<term>Néphrologie</term>
<term>Urologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Plasma exchange may be effective adjunctive treatment for renal vasculitis. We performed a systematic review and meta-analysis of randomized controlled trials of plasma exchange for renal vasculitis. Study Design: Systematic review and meta-analysis of articles identified from electronic databases, bibliographies, and studies identified by experts. Data were abstracted in parallel by 2 reviewers. Setting & Population: Adults with idiopathic renal vasculitis or rapidly progressive glomerulonephritis. Selection Criteria for Studies: Randomized controlled trials that compared standard care with standard care plus adjuvant plasma exchange in adult patients with either renal vasculitis or idiopathic rapidly progressive glomerulonephritis. Intervention: Adjuvant plasma exchange. Outcome: Composite of end-stage renal disease or death. Results: We identified 9 trials including 387 patients. In a fixed-effects model, the pooled RR for end-stage renal disease or death was 0.80 for patients treated with adjunctive plasma exchange compared with standard care alone (95% CI, 0.65-0.99; P = 0.04). No significant heterogeneity was detected (P = 0.5; I<sup>2</sup>
 = 0%). The effect of plasma exchange did not differ significantly across the range of baseline serum creatinine values (P = 0.7) or number of plasma exchange treatments (P = 0.8). The RR for end-stage renal disease was 0.64 (95% CI, 0.47-0.88; P= 0.006), whereas the RR for death alone was 1.01 (95% CI, 0.71-1.4; P= 0.9). Limitations: Although the primary result was statistically significant, there is insufficient statistical information to reliably determine whether plasma exchange decreases the composite of end-stage renal disease or death. Conclusions: Plasma exchange may decrease the composite end point of end-stage renal disease or death in patients with renal vasculitis. Additional trials are required given the limited data available.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0272-6386</s0>
</fA01>
<fA03 i2="1"><s0>Am. j. kidney dis.</s0>
</fA03>
<fA05><s2>57</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>WALSH (Michael)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CATAPANO (Fausta)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SZPIRT (Wladimir)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>THORLUND (Kristian)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BRUCHFELD (Annette)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>GUILLEVIN (Loic)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>HAUBITZ (Marion)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>MERKEL (Peter A.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>CHEN AU PEH</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>PUSEY (Charles)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>JAYNE (David)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Clinical Epidemiology and Biostatistics, McMaster University</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Vasculitis and Lupus Clinic, Addenbrooke's Hospital</s1>
<s2>Cambridge</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Nephrology, Copenhagen University Hospital, Rigshospitalet</s1>
<s2>Copenhagen</s2>
<s3>DNK</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Renal Medicine, Karolinska Institute, Karolinska University Hospital</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Hopital Cochin, Assistance Publique, Hopitaux de Paris, Universite Paris Descartes</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department ofNephrology and Hypertension, Hannover School of Medicine</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Renal Unit, Royal Adelaide Hospital</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Renal Section, Division of Medicine, Imperial College London, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA20><s1>566-574</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>19098</s2>
<s5>354000192894050130</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>35 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0199219</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>American journal of kidney diseases</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Plasma exchange may be effective adjunctive treatment for renal vasculitis. We performed a systematic review and meta-analysis of randomized controlled trials of plasma exchange for renal vasculitis. Study Design: Systematic review and meta-analysis of articles identified from electronic databases, bibliographies, and studies identified by experts. Data were abstracted in parallel by 2 reviewers. Setting & Population: Adults with idiopathic renal vasculitis or rapidly progressive glomerulonephritis. Selection Criteria for Studies: Randomized controlled trials that compared standard care with standard care plus adjuvant plasma exchange in adult patients with either renal vasculitis or idiopathic rapidly progressive glomerulonephritis. Intervention: Adjuvant plasma exchange. Outcome: Composite of end-stage renal disease or death. Results: We identified 9 trials including 387 patients. In a fixed-effects model, the pooled RR for end-stage renal disease or death was 0.80 for patients treated with adjunctive plasma exchange compared with standard care alone (95% CI, 0.65-0.99; P = 0.04). No significant heterogeneity was detected (P = 0.5; I<sup>2</sup>
 = 0%). The effect of plasma exchange did not differ significantly across the range of baseline serum creatinine values (P = 0.7) or number of plasma exchange treatments (P = 0.8). The RR for end-stage renal disease was 0.64 (95% CI, 0.47-0.88; P= 0.006), whereas the RR for death alone was 1.01 (95% CI, 0.71-1.4; P= 0.9). Limitations: Although the primary result was statistically significant, there is insufficient statistical information to reliably determine whether plasma exchange decreases the composite of end-stage renal disease or death. Conclusions: Plasma exchange may decrease the composite end point of end-stage renal disease or death in patients with renal vasculitis. Additional trials are required given the limited data available.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B14A01</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B07</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Echange plasmatique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Plasma exchange</s0>
<s5>02</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Intercambio plasmático</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Rein</s0>
<s5>03</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Kidney</s0>
<s5>03</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Riñón</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Vascularite</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Vasculitis</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Vasculitis</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Idiopathique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Idiopathic</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Idiopático</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Progressif</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Progressive</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Progresivo</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Néphropathie glomérulaire</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Glomerulonephritis</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Nefropatía glomerular</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Métaanalyse</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Metaanalysis</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Meta-análisis</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Néphrologie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Nephrology</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Nefrología</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Urologie</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Urology</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Urología</s0>
<s5>17</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Appareil urinaire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Urinary system</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato urinario</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie des vaisseaux sanguins</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Vascular disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Vaso sanguíneo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'appareil urinaire</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Urinary system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Aparato urinario patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du rein</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Kidney disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Riñón patología</s0>
<s5>41</s5>
</fC07>
<fN21><s1>129</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 11-0199219 INIST</NO>
<ET>Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis</ET>
<AU>WALSH (Michael); CATAPANO (Fausta); SZPIRT (Wladimir); THORLUND (Kristian); BRUCHFELD (Annette); GUILLEVIN (Loic); HAUBITZ (Marion); MERKEL (Peter A.); CHEN AU PEH; PUSEY (Charles); JAYNE (David)</AU>
<AF>Department of Clinical Epidemiology and Biostatistics, McMaster University/Hamilton/Canada (1 aut., 4 aut.); Vasculitis and Lupus Clinic, Addenbrooke's Hospital/Cambridge/Royaume-Uni (1 aut., 2 aut., 11 aut.); Department of Nephrology, Copenhagen University Hospital, Rigshospitalet/Copenhagen/Danemark (3 aut.); Department of Renal Medicine, Karolinska Institute, Karolinska University Hospital/Stockholm/Suède (5 aut.); Hopital Cochin, Assistance Publique, Hopitaux de Paris, Universite Paris Descartes/Paris/France (6 aut.); Department ofNephrology and Hypertension, Hannover School of Medicine/Hannover/Allemagne (7 aut.); Vasculitis Center, Section of Rheumatology, and the Clinical Epidemiology Unit, Boston University School of Medicine/Boston, MA/Etats-Unis (8 aut.); Renal Unit, Royal Adelaide Hospital/Adelaide/Australie (9 aut.); Renal Section, Division of Medicine, Imperial College London, Hammersmith Hospital/London/Royaume-Uni (10 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>American journal of kidney diseases; ISSN 0272-6386; Etats-Unis; Da. 2011; Vol. 57; No. 4; Pp. 566-574; Bibl. 35 ref.</SO>
<LA>Anglais</LA>
<EA>Background: Plasma exchange may be effective adjunctive treatment for renal vasculitis. We performed a systematic review and meta-analysis of randomized controlled trials of plasma exchange for renal vasculitis. Study Design: Systematic review and meta-analysis of articles identified from electronic databases, bibliographies, and studies identified by experts. Data were abstracted in parallel by 2 reviewers. Setting & Population: Adults with idiopathic renal vasculitis or rapidly progressive glomerulonephritis. Selection Criteria for Studies: Randomized controlled trials that compared standard care with standard care plus adjuvant plasma exchange in adult patients with either renal vasculitis or idiopathic rapidly progressive glomerulonephritis. Intervention: Adjuvant plasma exchange. Outcome: Composite of end-stage renal disease or death. Results: We identified 9 trials including 387 patients. In a fixed-effects model, the pooled RR for end-stage renal disease or death was 0.80 for patients treated with adjunctive plasma exchange compared with standard care alone (95% CI, 0.65-0.99; P = 0.04). No significant heterogeneity was detected (P = 0.5; I<sup>2</sup>
 = 0%). The effect of plasma exchange did not differ significantly across the range of baseline serum creatinine values (P = 0.7) or number of plasma exchange treatments (P = 0.8). The RR for end-stage renal disease was 0.64 (95% CI, 0.47-0.88; P= 0.006), whereas the RR for death alone was 1.01 (95% CI, 0.71-1.4; P= 0.9). Limitations: Although the primary result was statistically significant, there is insufficient statistical information to reliably determine whether plasma exchange decreases the composite of end-stage renal disease or death. Conclusions: Plasma exchange may decrease the composite end point of end-stage renal disease or death in patients with renal vasculitis. Additional trials are required given the limited data available.</EA>
<CC>002B14A01; 002B07</CC>
<FD>Echange plasmatique; Rein; Vascularite; Idiopathique; Progressif; Néphropathie glomérulaire; Métaanalyse; Néphrologie; Urologie</FD>
<FG>Appareil urinaire; Pathologie de l'appareil circulatoire; Pathologie des vaisseaux sanguins; Pathologie de l'appareil urinaire; Pathologie du rein</FG>
<ED>Plasma exchange; Kidney; Vasculitis; Idiopathic; Progressive; Glomerulonephritis; Metaanalysis; Nephrology; Urology</ED>
<EG>Urinary system; Cardiovascular disease; Vascular disease; Urinary system disease; Kidney disease</EG>
<SD>Intercambio plasmático; Riñón; Vasculitis; Idiopático; Progresivo; Nefropatía glomerular; Meta-análisis; Nefrología; Urología</SD>
<LO>INIST-19098.354000192894050130</LO>
<ID>11-0199219</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E28 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001E28 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:11-0199219
   |texte=   Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis

Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri